CNTA250117C25000
- 0.00
- 0.000.00%
Centessa Pharmaceuticals Newsroom
Centessa Pharmaceuticals: Promising Market Position and Growth Potential in Orexin Agonists for Narcolepsy
Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Shares Could Be 30% Below Their Intrinsic Value Estimate
Centessa Pharmaceuticals Secures Loan Facility, Repays Debt
Five Reasons Why UBS Is Overweight the UK
Why Did Centessa Pharmaceuticals PLC (CNTA) Jump Yesterday?
Centessa Pharmaceuticals Insider Sold Shares Worth $1,615,255, According to a Recent SEC Filing
Is Centessa Pharmaceuticals (NASDAQ:CNTA) Using Too Much Debt?
Insider Sale: Chief Executive Officer of $CNTA (CNTA) Sells 1,671 Shares
Maximus Reports Weak Earnings, Joins Atkore, PDD Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Leerink Partners Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Announces Target Price $24
Centessa Pharmaceuticals Is Maintained at Buy by Guggenheim
Guggenheim Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Raises Target Price to $28
Morgan Stanley Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Raises Target Price to $27
BMO Capital Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $35
Morgan Stanley Lifts Price Target on Centessa Pharmaceuticals to $27 From $26, Keeps Overweight Rating
Express News | Centessa Pharmaceuticals PLC : Jefferies Raises Target Price to $27 From $19
Centessa Pharmaceuticals Strengthens Financial Position Amid Losses
B.Riley Financial Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Maintains Target Price $33
Centessa Pharmaceuticals: Promising Pipeline and Strategic Focus Drive Buy Rating
Centessa Pharmaceuticals Advances Pipeline With Promising OX2R Data